Breakthrough study tests if longer treatment can stop devastating autoimmune disease from returning

This study tested whether giving rituximab (a medication that calms the immune system) for a longer time could better prevent relapses in people with ANCA-associated vasculitis—a serious autoimmune disease that causes blood vessel inflammation. The trial involved 97 patients who were already in remission after initial treatment and randomly assigned them to receive either extended rituximab infusions or a placebo, to see which group stayed relapse-free longer. The goal was to find the optimal treatment duration to keep this chronic condition under control and prevent dangerous flare-ups.